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DISPATCHES
Amid the coronavirus disease (COVID-19) pan-demic, multisystem infl ammatory syndrome 
in children (MIS-C) has emerged as a major concern 
globally (1). MIS-C features clinical characteristics 
that overlap with Kawasaki disease, including high 
fever, mucocutaneous involvement, and affecting of 
coronary arteries. Yet, reports of MIS-C have been 
limited in East Asia countries, where the incidence of 
Kawasaki disease is high (2).
Although South Korea was one of the countries 
struck early in the COVID-19 pandemic, spread of the 
virus there has been relatively contained. However, 
reports on MIS-C from other countries has necessi-
tated the monitoring of COVID-19–associated MIS-C 
at the national level. In May 2020, the Korean Soci-
ety of Pediatric Infectious Diseases, Korean Society 
of Kawasaki Disease, and Korean Society of Pediatric 
Critical Care Medicine, with support from the Korea 
Disease Control and Prevention Agency, created a 
strategic framework for prospective surveillance of 
MIS-C in South Korea. In this study, we describe the 
development of the MIS-C surveillance system and 
report the clinical characteristics of children meeting 
the case defi nition of MIS-C in South Korea.
The Study
First, the Case Assessment Committee (CAC) was 
established, consisting of 4 pediatric infectious dis-
ease specialists, 3 pediatric cardiologists, 3 pediatric 
intensivists, 1 clinical microbiologist, and 1 epidemi-
ologist. A case reporting form was created, and mem-
bers of the Korean Pediatric Society (n = 5,891) were 
contacted to provide assistance with data collection 
and reporting.
Once a suspected MIS-C case was reported, CAC 
members quickly assessed whether the case met the 
clinical criteria for MIS-C case defi nition. In accor-
dance with the Infectious Disease Control and Pre-
vention Act (chapter 4, article 18), the public health 
offi cers then conducted an epidemiologic investiga-
tion of all suspected MIS-C cases. For all reported cas-
es, the Korea Disease Control and Prevention Agency 
performed serologic assays for severe acute respirato-
ry syndrome coronavirus 2 (SARS-CoV-2), including 
neutralizing antibody tests and the Anti-SARS-CoV-2 
ELISA Assay for detection of IgG (EUROIMMUN, 
https://www.euroimmun.com). CAC meetings 
were held on an ad hoc basis for case ascertainment, 
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A concerning development during the coronavirus dis-
ease pandemic has been multisystem infl ammatory 
syndrome in children. Reports of this condition in East 
Asia have been limited. In South Korea, 3 cases were 
reported to the national surveillance system for multi-
system infl ammatory syndrome in children. All case-
patients were hospitalized and survived with no major 
disease sequelae.
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treatment consultation, and exchange of knowledge. 
The study was approved by the Institutional Review 
Board of Seoul National University Hospital (approv-
al no. 2012–136–118).
During May–November 2020, a total of 2,287 
COVID-19 cases in persons 0–19 years of age were 
reported (Figure). During the surveillance period, 9 
suspected cases of MIS-C were reported to the sur-
veillance system. Of the reported cases, 3 (33%) case-
patients had evidence of COVID-19 exposure (posi-
tive for SARS-CoV-2 by PCR, SARS-CoV-2 antibody 
detection, or exposure history), and their illness was 
assessed as COVID-19–associated MIS-C, which 
likely occurred 3–4 weeks after the diagnosis of CO-
VID-19 (Table).
The age of case-patients ranged from 11 to 14 
years, 2 were boys, and none had preexisting con-
ditions. All case-patients had fever and abdominal 
symptoms (abdominal pain, nausea, vomiting, or di-
arrhea) at admission. Mucocutaneous symptoms and 
signs (mucosal changes, skin rash, extremity chang-
es) occurred in 2 patients, and all patients had docu-
mented hypotension (<50th percentile, adjusted for 
age, sex, and height). All case-patients had marked 
leukocytosis or elevated inflammatory markers. 
Echocardiography showed coronary artery dilata-
tion (z-scores 1.64–3.98 mm for left coronary arteries), 
mitral regurgitation, or left ventricular dysfunction. 
Chest radiography or computed tomography showed 
pulmonary edema or pleural effusion. Abdominal 
ultrasound or computed tomography showed mes-
enteric lymphadenopathies, hyperechoic liver, or hy-
pertrophic gall bladder. All 3 case-patients received 
intravenous immunoglobulin (IVIg); 1 patient (case 
3) received methylprednisolone pulse therapy and 
immunomodulatory agent (Anakinra) because of 
persistent hypotension after initial IVIg treatment. 
Two patients received inotropic agents and required 
transfer to the intensive care unit (ICU), but no pa-
tients required mechanical ventilation. The duration 
of hospitalization was 10–19 days, and duration of 
ICU admission was 6–7 days. All 3 patients received 
aspirin and have survived to date with no major dis-
ease sequelae.
Conclusions
We describe MIS-C surveillance results from South 
Korea, an East Asia country with high incidence of 
Kawasaki disease. As of December 15, 2020, CO-
VID-19 had been diagnosed in 4,107 children and 
adolescents 0–19 years of age in South Korea, which 
translates roughly to 0.07% of all childhood CO-
VID-19 cases reported in South Korea (3). Concern 
about MIS-C was raised after episodes of increased 
incidence of Kawasaki-like disease were noted in 
children after COVID-19 diagnosis in Europe and 
the United States (4,5). In South Korea, there was 
no substantial increase in Kawasaki disease–related 
hospitalizations in 2020 compared with 2016–2019 
(6). There might be ethnic differences in suscepti-
bility; only 5% of MIS-C cases in New York (USA) 
occurred in Asian persons (7). Reports from India 
(8), Pakistan (9), and Iran (10) underscore the im-
portance of monitoring MIS-C cases; however, sur-
veillance data have not yet been reported for East 
Asia countries. Alongside genetic susceptibility, the 
Figure. Daily number (bars) and cumulative number (line) of COVID-19 cases among children 0–19 years of age, South Korea, May–
November 2020. The occurrences of the 3 cases of multisystem inflammatory syndrome are indicated. COVID-19, coronavirus disease; 
MIS-C, multisystem inflammatory syndrome in children.
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background incidence of SARS-CoV-2 infection 
might play a critical role in the occurrence of MIS-C. 
Although estimates of risk for MIS-C after SARS-
CoV-2 infection are not yet available, we report a 
rough estimate in South Korea, where COVID-19 test-
ing is widely accessible (11). Our findings suggest that 
the incidence of MIS-C is low among children with 
COVID-19 in this country. However, COVID-19–as-
sociated MIS-C might cause serious clinical outcomes 
requiring ICU care and might require immunomodu-
latory agents.
All 3 MIS-C case-patients experienced gas-
trointestinal symptoms, which is consistent with 
reports from Italy (5), the United States (12), and 
the United Kingdom (13) that indicate gastrointes-
tinal symptoms appear to be the most prominent 
 
Table. Demographics, clinical features, treatments, and outcomes of the 3 COVID-19–associated MIS-C case-patients, South Korea, 
May–November 2020* 
Characteristics Case 1 Case 2 Case 3 
Age, y 11 11 14 
Sex Boy Boy Girl 
Underlying disease None None None 
Clinical signs and symptoms 
   
 Initial symptoms Fever, abdominal pain Fever, abdominal pain, 
headache, nausea, vomiting 
Fever, abdominal pain, 
diarrhea 
 Fever Present Present Present 
 Conjunctival injection Present Present Present 
 Mucosal change Present None Present 
 Skin rash Present None Present 
 Extremity changes Present None Present 
 Lymphadenopathy None None None 
 Gastrointestinal symptoms Present Present Present 
 Hypotension Present Present Present 
Inflammatory markers (peak) 
   
 Leukocyte (neutrophil %), 103/μL 7.55 (87) 9.55 (82.8) 26.56 (93) 
 ESR, mm/h NT 82 77 
 CRP, mg/L 18.95 10.36 >30 
 Fibrinogen, mg/dL 633 NT NT 
 Procalcitonin, ng/mL 14.55 1.54 9.62 
 D-dimer, μg/mL 894 2.5 3.95 
 Ferritin, μg/mL NT 2485 663 
 IL-6, pg/mL NT NT 2410 
Abnormal imaging studies  
   
 Echocardiography Coronary dilatation Mitral regurgitation Coronary dilatation, left 
ventricle dysfunction 




Bilateral pulmonary edema, 
pleural effusion 







fluids, splenomegaly, scant 
pelvic ascites 
Treatment 
   
 IVIg Provided Provided Provided 
 ASA Provided Provided Provided 
 Steroids Not provided Not provided Provided 
 Immunomodulatory Not provided Not provided Provided (Anakinra) 
 Inotropic agent Provided Not provided Provided 
 ICU care Provided Not provided Provided 
 Mechanical ventilator Not provided Not provided Not provided 
Outcome 
   
 Hospitalization, d 12 d 10 d 19 d 
 ICU admission, d 6 d NA 7 d 
 Prognosis Improved, discharged Improved, discharged Improved, discharged 
*MIS-C clinical case definition is as follows: age <19 y, fever >38.0°C for >24 h, laboratory evidence of inflammation (i.e., elevation of ESR, CRP, 
fibrinogen, procalcitonin, d-dimer, ferritin, LDH, IL-6, neutrophilia, lymphopenia, hypoalbuminemia), multisystem involvement (>2 organ systems involved), 
severe illness requiring hospitalization, and no other plausible microbial cause of inflammation (i.e., bacterial sepsis, staphylococcal/streptococcal toxic 
shock syndromes, enteroviral myocarditis). Evidence of SARS-CoV-2 exposure history defined as positive SARS-CoV-2 by RT-PCR, positive serology 
(neutralizing antibody or anti-SARS-CoV-2 IgG), or exposure to individual with COVID-19 <4 weeks before onset of symptoms (epidemiologic linkage with 
individual or cluster). ASA, acetylsalicylic acid; COVID-19, coronavirus disease 2; CRP, c-reactive protein; CT, computed tomography; ESR, erythrocyte 
sedimentation rate; ICU, intensive care unit; IL-6, interleukin 6; IVIg, intravenous immunoglobulin; LDH, lactate dehydrogenase; MIS-C, multisystem 
inflammatory syndrome in children; NA, not applicable; NT, not tested; RT-PCR, reverse transcription PCR; SARS-CoV-2, severe acute respiratory 
syndrome coronavirus 2.  
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clinical manifestation of MIS-C. Gastrointestinal in-
volvement might also be a predictor of severe CO-
VID-19. A systematic review of 83 studies showed 
that diarrhea (odds ratio 1.50, 95% CI 1.10–2.03; p = 
0.01) was observed more often in patients with se-
vere COVID-19 compared with patients with non-
severe COVID-19 (14). Previously, syndromic in-
volvement of the gastrointestinal system has been 
associated with higher risk for IVIg resistance and 
coronary aneurysms in patients with Kawasaki dis-
ease (15). These features indicate the possibility of 
a mechanism linking gastrointestinal involvement 
and syndromic features for MIS-C and Kawasaki-
like illness, which needs further elucidation.
The first limitation of this study is that, given the 
intrinsic properties of a passive surveillance system, 
only a fraction of actual MIS-C cases might have been 
reported. Pediatricians are more likely to report cases 
that result in serious conditions; nonetheless, the case 
definition included hospitalization. Second, a large 
proportion of SARS-CoV-2 infections in children are 
asymptomatic; therefore, passive surveillance that 
relies on the presence of symptoms might underes-
timate the actual incidence of MIS-C. Despite these 
limitations, this study suggests that enhanced passive 
surveillance, including frequent outreach to pediatri-
cians through academic societies, was a manageable 
scheme to monitor MIS-C in South Korea. Given that 
the level of SARS-CoV-2 community transmission 
was low during the surveillance period, passive sur-
veillance was considered a robust plan to capture 
MIS-C cases at a national level.
Despite the introduction of vaccines, the global 
COVID-19 pandemic could continue for months. 
Therefore, surveillance is a critical tool for the detec-
tion and evaluation of serious complications in vul-
nerable population. Our experience offers a possible 
surveillance model for other countries concerned 
about COVID-19–associated MIS-C. MIS-C surveil-
lance data in South Korea call for enhanced monitor-
ing through syndromic and laboratory-based combi-
nation surveillance approaches.
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